OvaSave

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOvaSave

Drug Alias NameOva-TregAg-Treg cell therapy (TxCell)Autologous Tr1 cell therapy (TxCell)

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs

Mechanisms of ActionT lymphocyte replacementsImmunosuppressants

TargetsNot applicable

Therapy Area/IndicationsCrohn Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumItalyAustria +[6]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTxcell

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTxcell

Active IndicationsN/A

Inactive IndicationsCrohn Disease

Other Information

ATC CodeN/A